POSA236 Real-World Treatment (Tx) Characteristics for Advanced Non-Small Cell Lung Cancer (aNSCLC) Without Actionable Mutations After Introduction of Immune Checkpoint Inhibitors (ICIs) in EU4 and UK
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.751
https://www.valueinhealthjournal.com/article/S1098-3015(21)02546-8/fulltext
Section Title :
Section Order :
10279
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02546-8&doi=10.1016/j.jval.2021.11.751